title: Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes.
abstract: BACKGROUND
  To investigate the efficacy of ranibizumab therapy for choroidal neovascular (CNV) membranes secondary to conditions other than macular degeneration.
  
  
  METHODS
  Prospective case series conducted at the Royal Victorian Eye and Ear Hospital.
  
  
  METHODS
  Twelve-month follow-up data for 41 patients with CNV recruited from the outpatient clinic from May 2008 to April 2010 is presented. Fifteen patients had myopia, seven had multifocal choroiditis, and eight had other primary causes.
  
  
  METHODS
  All patients had visual acuity, fluorescein angiogram and optical coherence tomography performed at the initial visit (baseline). Ranibizumab was injected with a standard sterile technique. Patients were reviewed after 1 month, and further injections were given at the treating doctors' discretion.
  
  
  METHODS
  Change in visual acuity and central macular thickness at 12 months was compared with baseline for each of the groups. Local and systemic adverse outcomes were recorded.
  
  
  RESULTS
  Analysis was stratified by primary pathology. On average, 40%, 43% and 25% of patients with myopia, multifocal choroiditis and 'other' pathologies, respectively, experienced a three or more line improvement in vision. The average number of injections in 12 months was 4.2 for the entire group. Central macular thickness significantly decreased in the 12-month period for the combined group (P = 0.03). No patient had an adverse systemic side-effect; however, there was one case of endophthalmitis.
  
  
  CONCLUSIONS
  Ranibizumab is an effective treatment for CNV secondary to non-age-related macular degeneration causes, with most patients gaining an improvement in the first 2 months following injection.
authors: Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
authors: Robyn
authors: R
authors: Troutbeck
authors: Roland
authors: R
authors: Bunting
authors: Anton
authors: A
authors: van Heerdon
authors: Melinda
authors: M
authors: Cain
authors: Robyn
authors: R
authors: Guymer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002833:Choroiditis / Q000150:complications*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000150:complications*; D011446:Prospective Studies; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab